DiaMedica's DM-199 for Type 1 Diabetes Significantly Delays Autoimmune Attack

[Northerner]

DiaMedica Inc. is pleased to announce new compelling Type 1 diabetes data. An in vivo study with the chronic administration of DM-199 significantly delayed the autoimmune attack, preserved beta cell mass and demonstrated a 12-fold increase in circulating C-peptide levels in the non-obese diabetic (NOD) animal model.

http://www.marketwatch.com/story/di...-levels-2011-12-05-82180?reflink=MW_news_stmp